{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.clinicalstudies.in/sop-for-device-accountability-calibration-and-maintenance”
},
“headline”: “SOP for Device Accountability, Calibration and Maintenance”,
“description”: “This SOP outlines the standardized process for accountability, calibration, and maintenance of devices used in clinical trials, ensuring compliance with FDA, EMA, CDSCO, WHO, and ICH GCP requirements for investigational devices and trial-related equipment.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}

Standard Operating Procedure for Device Accountability, Calibration and Maintenance

Purpose

The purpose of this SOP is to define standardized procedures for the accountability, calibration, and maintenance of devices used in clinical trials. Proper management of devices ensures reliability of data, subject safety, regulatory compliance, and inspection readiness.

Scope

This SOP applies to all investigational devices and equipment used in clinical trials, including diagnostic instruments, monitoring devices, laboratory equipment, and therapeutic devices. It covers device receipt, storage, accountability, calibration, preventive and corrective maintenance, documentation, and disposal.

Responsibilities

• Sponsor: Ensures overall compliance with device accountability and calibration requirements.
• Investigator/Site Staff: Maintain device logs, perform accountability, and ensure timely calibration and maintenance.
• CRA: Verifies device accountability during monitoring visits.
• QA: Reviews calibration and maintenance records for compliance.
• Vendors: Provide calibration certificates and maintenance support.

Accountability

The Principal Investigator is accountable for site-level device accountability, calibration, and maintenance. Sponsor QA is accountable for ensuring oversight and compliance across sites and vendors.

Procedure

1. Device Receipt and Accountability
1.1 Record device receipt in Device Accountability Log (Annexure-1).
1.2 Verify device identification, serial numbers, and condition upon receipt.
1.3 Store devices securely with restricted access.

2. Device Calibration
2.1 Calibrate devices prior to study initiation and at defined intervals.
2.2 Use qualified vendors or accredited laboratories.
2.3 Retain calibration certificates in Calibration Certificate File (Annexure-2).

3. Device Maintenance
3.1 Perform preventive maintenance as per manufacturer’s guidelines.
3.2 Record all maintenance activities in Maintenance Log (Annexure-3).
3.3 Address corrective maintenance promptly when malfunctions occur.

4. Device Use Tracking
4.1 Record device use in Device Use Log (Annexure-4).
4.2 Reconcile device usage with study records.

5. Device Disposal/Return
5.1 At study completion, return or dispose of devices per sponsor/vendor instructions.
5.2 Document in Device Disposal Log (Annexure-5).

Abbreviations

• SOP: Standard Operating Procedure
• CRA: Clinical Research Associate
• QA: Quality Assurance
• PI: Principal Investigator
• IDE: Investigational Device Exemption
• WHO: World Health Organization

Documents

1. Device Accountability Log (Annexure-1)
2. Calibration Certificate File (Annexure-2)
3. Maintenance Log (Annexure-3)
4. Device Use Log (Annexure-4)
5. Device Disposal Log (Annexure-5)

References

• ICH E6(R2/R3) – Device Management Standards
• FDA 21 CFR Part 812 – Investigational Device Exemptions
• EMA – Medical Device Trials Guidelines
• CDSCO – Device Accountability and Calibration
• WHO – Medical Device Accountability and Maintenance

Version: 1.0

Approval Section

Annexures

Annexure-1: Device Accountability Log

Annexure-2: Calibration Certificate File

Annexure-3: Maintenance Log

Annexure-4: Device Use Log

Annexure-5: Device Disposal Log

Revision History

For more SOPs visit: Pharma SOP

{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.clinicalstudies.in/sop-for-device-labeling-and-udi-considerations-in-trials”
},
“headline”: “SOP for Device Labeling and UDI Considerations in Trials”,
“description”: “This SOP describes procedures for device labeling and unique device identification (UDI) in clinical trials. It ensures compliance with FDA, EMA, CDSCO, WHO, and ICH GCP requirements for investigational devices, covering label creation, verification, traceability, and regulatory submissions.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}

Standard Operating Procedure for Device Labeling and UDI Considerations in Trials

Purpose

The purpose of this SOP is to define procedures for labeling investigational devices and applying Unique Device Identification (UDI) requirements in clinical trials. Proper labeling ensures device traceability, subject safety, regulatory compliance, and consistency across global studies.

Scope

This SOP applies to sponsors, investigators, CROs, device manufacturers, packaging vendors, and site staff involved in device trials. It covers creation, verification, application, reconciliation, and inspection readiness of device labels including UDI elements.

Responsibilities

• Sponsor: Defines labeling requirements and ensures global regulatory compliance.
• Device Manufacturer: Generates labels with UDI codes and trial-specific identifiers.
• Investigator/Site Staff: Verify labeling before device use at the site.
• CRA: Monitors label compliance during site visits.
• QA: Reviews and audits labeling processes and records.

Accountability

The Sponsor’s Device Quality Lead is accountable for ensuring device labeling and UDI compliance across studies. The Investigator is accountable for verifying site-level device labels prior to use.

Procedure

1. Label Creation
1.1 Labels must include trial identifier, device ID, UDI code, storage instructions, and cautionary statements.
1.2 Generate labels according to regulatory and protocol requirements.
1.3 Document creation in Label Creation Log (Annexure-1).

2. Label Application
2.1 Apply labels at manufacturer or central packaging site under controlled conditions.
2.2 Ensure barcodes/UDI codes are scannable and legible.
2.3 Record in Label Application Log (Annexure-2).

3. Label Verification
3.1 Verify label accuracy against approved text and trial-specific requirements.
3.2 Document verification in Label Verification Log (Annexure-3).

4. Label Reconciliation
4.1 Reconcile issued, applied, unused, and destroyed labels.
4.2 Maintain reconciliation records in Label Reconciliation Log (Annexure-4).

5. Label Corrections/Re-labeling
5.1 Perform re-labeling under controlled, documented conditions.
5.2 Record re-labeling activities in Re-labeling Log (Annexure-5).

6. UDI Compliance
6.1 Register device UDI in appropriate regulatory databases (FDA GUDID, EU EUDAMED).
6.2 Ensure UDI elements are linked to trial-specific records.

7. Archiving
7.1 Archive all labeling records in TMF and site ISF.
7.2 Retain according to regulatory requirements.

Abbreviations

• SOP: Standard Operating Procedure
• UDI: Unique Device Identification
• CRA: Clinical Research Associate
• QA: Quality Assurance
• PI: Principal Investigator
• TMF: Trial Master File
• ISF: Investigator Site File
• GUDID: Global Unique Device Identification Database
• EUDAMED: European Database on Medical Devices

Documents

1. Label Creation Log (Annexure-1)
2. Label Application Log (Annexure-2)
3. Label Verification Log (Annexure-3)
4. Label Reconciliation Log (Annexure-4)
5. Re-labeling Log (Annexure-5)

References

• FDA – Unique Device Identification (UDI) System
• EMA/EU – EUDAMED Database and Device Labeling
• ICH E6(R2/R3) – Device Trials Labeling Guidance
• CDSCO – Device Labeling Requirements
• WHO – Medical Device Labeling and UDI Recommendations

Version: 1.0

Approval Section

Annexures

Annexure-1: Label Creation Log

Annexure-2: Label Application Log

Annexure-3: Label Verification Log

Annexure-4: Label Reconciliation Log

Annexure-5: Re-labeling Log

Revision History

For more SOPs visit: Pharma SOP

{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.clinicalstudies.in/sop-for-drug-device-combination-products-oversight”
},
“headline”: “SOP for Drug-Device Combination Products Oversight”,
“description”: “This SOP outlines the oversight procedures for clinical trials involving drug-device combination products. It ensures compliance with FDA, EMA, CDSCO, WHO, and ICH GCP requirements for accountability, labeling, risk management, quality oversight, and reporting.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}

Standard Operating Procedure for Drug-Device Combination Products Oversight

Purpose

The purpose of this SOP is to establish standardized oversight procedures for clinical trials involving drug-device combination products. It ensures that both drug and device components are managed, documented, and monitored in compliance with global regulatory requirements, maintaining subject safety and data integrity.

Scope

This SOP applies to sponsors, investigators, CROs, vendors, and site staff engaged in the conduct of drug-device combination clinical trials. It covers accountability, labeling, storage, calibration, quality oversight, safety monitoring, adverse event reporting, and regulatory submissions.

Responsibilities

• Sponsor: Ensures oversight of drug-device combination products, including regulatory compliance and quality management.
• Investigator/Site Staff: Maintain accountability and logs for both drug and device components.
• CRO: Monitors site compliance and supports sponsor oversight.
• QA: Audits documentation and verifies compliance with GCP.
• Vendors: Provide calibration, labeling, and certification support.

Accountability

The Sponsor’s Quality Lead is accountable for ensuring drug-device combination product compliance. Investigators are accountable for site-level management of products. QA is accountable for verification and audit readiness.

Procedure

1. Product Receipt and Accountability
1.1 Record receipt of drug-device products in the Combination Product Accountability Log (Annexure-1).
1.2 Verify labeling, packaging, and integrity upon receipt.
1.3 Store products according to defined environmental conditions.

2. Labeling and Identification
2.1 Ensure labeling includes “For Clinical Trial Use Only” and UDI identifiers.
2.2 Document labeling in the Labeling Log (Annexure-2).

3. Storage and Handling
3.1 Store per drug storage guidelines (e.g., temperature, humidity) and device requirements (e.g., calibration status).
3.2 Restrict access to authorized personnel only.

4. Calibration and Maintenance
4.1 Ensure device components undergo calibration per manufacturer requirements.
4.2 Record activities in Calibration and Maintenance Log (Annexure-3).

5. Risk Management
5.1 Conduct risk assessment for drug-device interactions and trial-specific risks.
5.2 Document in Risk Assessment Log (Annexure-4).

6. Safety Monitoring and AE Reporting
6.1 Monitor both drug and device components for adverse events or malfunctions.
6.2 Report adverse events, device deficiencies, and malfunctions to sponsor, EC/IRB, and regulators as applicable.

7. Regulatory Submissions
7.1 Submit required documentation for combination products to FDA, EMA, CDSCO, or other authorities.
7.2 Maintain submission records in Regulatory Submission Log (Annexure-5).

8. Archiving
8.1 Archive all accountability, labeling, and safety records in TMF/ISF.
8.2 Retain as per regional archiving regulations.

Abbreviations

• SOP: Standard Operating Procedure
• QA: Quality Assurance
• CRO: Contract Research Organization
• TMF: Trial Master File
• ISF: Investigator Site File
• AE: Adverse Event
• UDI: Unique Device Identification
• FDA: Food and Drug Administration
• EMA: European Medicines Agency
• CDSCO: Central Drugs Standard Control Organization
• WHO: World Health Organization

Documents

1. Combination Product Accountability Log (Annexure-1)
2. Labeling Log (Annexure-2)
3. Calibration and Maintenance Log (Annexure-3)
4. Risk Assessment Log (Annexure-4)
5. Regulatory Submission Log (Annexure-5)

References

• FDA – Combination Products Guidance
• EMA – Clinical Trials with Combination Products
• CDSCO – Combination Product Regulations
• ICH GCP – Combination Products Oversight
• WHO – Global Oversight of Combination Trials

Version: 1.0

Approval Section

Annexures

Annexure-1: Combination Product Accountability Log

Annexure-2: Labeling Log

Annexure-3: Calibration and Maintenance Log

Annexure-4: Risk Assessment Log

Annexure-5: Regulatory Submission Log

Revision History

For more SOPs visit: Pharma SOP

{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.clinicalstudies.in/sop-for-ivd-trial-sample-handling-and-reporting”
},
“headline”: “SOP for IVD Trial Sample Handling and Reporting”,
“description”: “This SOP defines standardized procedures for handling and reporting samples in in vitro diagnostic (IVD) clinical trials, ensuring compliance with FDA, EMA, CDSCO, WHO, and ICH GCP requirements. It covers collection, processing, shipment, chain of custody, result reporting, and quality oversight.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}

Standard Operating Procedure for IVD Trial Sample Handling and Reporting

Purpose

The purpose of this SOP is to establish standardized procedures for handling and reporting samples in in vitro diagnostic (IVD) clinical trials. Proper sample handling and accurate reporting ensure subject safety, data integrity, regulatory compliance, and validity of trial outcomes.

Scope

This SOP applies to all sponsors, CROs, investigators, laboratories, and site staff involved in IVD clinical trials. It covers sample collection, labeling, processing, storage, shipment, chain of custody, laboratory testing, result reporting, and archiving of records.

Responsibilities

• Sponsor: Oversees IVD trial sample handling and ensures compliance with global regulations.
• Investigator/Site Staff: Responsible for accurate sample collection, labeling, and shipment.
• Laboratories: Perform sample analysis and maintain reporting accuracy.
• CRO: Monitors compliance with sample handling SOPs across sites.
• QA: Audits sample handling and reporting processes for accuracy and GCP compliance.

Accountability

The Investigator is accountable for site-level IVD sample handling and reporting. The Sponsor is accountable for ensuring oversight, data quality, and regulatory submission compliance.

Procedure

1. Sample Collection
1.1 Collect samples per study protocol and informed consent requirements.
1.2 Label each sample with subject ID, date, time, and trial identifier.
1.3 Record in Sample Collection Log (Annexure-1).

2. Sample Processing
2.1 Process samples as per laboratory manual (centrifugation, aliquoting, stabilization).
2.2 Document processing steps in Sample Processing Log (Annexure-2).

3. Sample Storage
3.1 Store samples under specified conditions (temperature, humidity, light protection).
3.2 Maintain storage records in Sample Storage Log (Annexure-3).

4. Sample Shipment
4.1 Ship samples using validated containers and cold-chain management.
4.2 Document shipment details in Sample Shipment Log (Annexure-4).

5. Chain of Custody
5.1 Maintain custody records from collection through analysis.
5.2 Ensure only authorized personnel handle samples.
5.3 Record in Chain of Custody Log (Annexure-5).

6. Result Reporting
6.1 Laboratories generate validated results and transmit securely to sponsor.
6.2 Record results in Result Reporting Log (Annexure-6).
6.3 Address discrepancies in reporting promptly.

7. Archiving
7.1 Archive sample records, logs, and test results in TMF and ISF.
7.2 Retain records per regulatory requirements.

Abbreviations

• SOP: Standard Operating Procedure
• IVD: In Vitro Diagnostic
• QA: Quality Assurance
• CRO: Contract Research Organization
• TMF: Trial Master File
• ISF: Investigator Site File
• FDA: Food and Drug Administration
• EMA: European Medicines Agency
• CDSCO: Central Drugs Standard Control Organization
• WHO: World Health Organization

Documents

1. Sample Collection Log (Annexure-1)
2. Sample Processing Log (Annexure-2)
3. Sample Storage Log (Annexure-3)
4. Sample Shipment Log (Annexure-4)
5. Chain of Custody Log (Annexure-5)
6. Result Reporting Log (Annexure-6)

References

• FDA – In Vitro Diagnostics Guidance
• EMA – IVD Regulation (IVDR)
• CDSCO – IVD Clinical Performance Evaluation
• ICH GCP – Sample Handling Standards
• WHO – Best Practices for IVD Trials

Version: 1.0

Approval Section

Annexures

Annexure-1: Sample Collection Log

Annexure-2: Sample Processing Log

Annexure-3: Sample Storage Log

Annexure-4: Sample Shipment Log

Annexure-5: Chain of Custody Log

Annexure-6: Result Reporting Log

Revision History

For more SOPs visit: Pharma SOP

{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.clinicalstudies.in/sop-for-atmp-trial-design-and-submissions-advanced-therapies”
},
“headline”: “SOP for ATMP Trial Design and Submissions (Advanced Therapies)”,
“description”: “This SOP provides standardized guidance for designing clinical trials and preparing regulatory submissions for Advanced Therapy Medicinal Products (ATMPs). It ensures compliance with FDA, EMA, CDSCO, WHO, and ICH GCP requirements, covering protocol design, dossier preparation, ethics submissions, and global trial oversight.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}

Standard Operating Procedure for ATMP Trial Design and Submissions (Advanced Therapies)

Purpose

The purpose of this SOP is to establish standardized procedures for the design and regulatory submissions of clinical trials involving Advanced Therapy Medicinal Products (ATMPs), including gene therapies, cell therapies, and tissue-engineered products. This ensures patient safety, data integrity, and regulatory compliance across regions.

Scope

This SOP applies to sponsors, investigators, CROs, regulatory affairs specialists, and QA teams involved in ATMP clinical trials. It covers trial design, protocol development, ethics and regulatory submissions, dossier preparation, global submission requirements, and oversight of ATMP-specific risks and long-term follow-up.

Responsibilities

• Sponsor: Oversees ATMP trial design, dossier preparation, and regulatory submissions.
• Regulatory Affairs: Prepares and manages submissions to FDA, EMA, CDSCO, and other authorities.
• Investigator: Ensures proper design and execution of ATMP trials at site level.
• CRO: Supports monitoring and documentation for ATMP compliance.
• QA: Verifies adherence to ATMP-specific GCP and GMP requirements.

Accountability

The Sponsor’s Head of Regulatory Affairs is accountable for ensuring ATMP trial design and submissions meet global regulatory requirements. Investigators are accountable for site-level trial execution.

Procedure

1. Trial Design
1.1 Define study objectives, endpoints, and patient population.
1.2 Conduct risk-benefit assessment specific to ATMPs.
1.3 Design inclusion/exclusion criteria addressing ATMP risks.
1.4 Document in ATMP Trial Design Log (Annexure-1).

2. Protocol Development
2.1 Develop protocol including manufacturing, administration, and follow-up requirements.
2.2 Include long-term follow-up design for gene and cell therapies.
2.3 Record in Protocol Development Log (Annexure-2).

3. Ethics and Regulatory Submissions
3.1 Submit trial documents to EC/IRB for review and approval.
3.2 Submit to regulatory authorities (FDA IND, EMA CTA, CDSCO CTN/CTA).
3.3 Maintain Regulatory Submission Log (Annexure-3).

4. Dossier Preparation
4.1 Prepare dossier with preclinical, manufacturing, and clinical data.
4.2 Ensure compliance with region-specific ATMP requirements.
4.3 Record in Dossier Preparation Log (Annexure-4).

5. Risk Management
5.1 Develop Risk Management Plan addressing ATMP-specific risks.
5.2 Maintain in Risk Management Log (Annexure-5).

6. Global Oversight
6.1 Coordinate submissions across multiple regions.
6.2 Track approvals and responses in Global Oversight Log (Annexure-6).

7. Archiving
7.1 Archive trial design, submission, and approval records in TMF.
7.2 Retain records as per regulatory timelines.

Abbreviations

• SOP: Standard Operating Procedure
• ATMP: Advanced Therapy Medicinal Products
• QA: Quality Assurance
• CRO: Contract Research Organization
• TMF: Trial Master File
• FDA: Food and Drug Administration
• EMA: European Medicines Agency
• CDSCO: Central Drugs Standard Control Organization
• IRB/EC: Institutional Review Board/Ethics Committee
• CTA: Clinical Trial Application
• CTN: Clinical Trial Notification
• IND: Investigational New Drug Application

Documents

1. ATMP Trial Design Log (Annexure-1)
2. Protocol Development Log (Annexure-2)
3. Regulatory Submission Log (Annexure-3)
4. Dossier Preparation Log (Annexure-4)
5. Risk Management Log (Annexure-5)
6. Global Oversight Log (Annexure-6)

References

• FDA – Cellular & Gene Therapy Guidance
• EMA – ATMP Guidelines
• CDSCO – ATMP Clinical Trial Rules
• ICH GCP – ATMP Trial Guidance
• WHO – Advanced Therapy Medicinal Products Recommendations

Version: 1.0

Approval Section

Annexures

Annexure-1: ATMP Trial Design Log

Annexure-2: Protocol Development Log

Annexure-3: Regulatory Submission Log

Annexure-4: Dossier Preparation Log

Annexure-5: Risk Management Log

Annexure-6: Global Oversight Log

Revision History

For more SOPs visit: Pharma SOP

{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.clinicalstudies.in/sop-for-chain-of-identity-and-chain-of-custody-cell-gene”
},
“headline”: “SOP for Chain of Identity & Chain of Custody (Cell/Gene)”,
“description”: “This SOP establishes procedures for maintaining chain of identity and chain of custody in cell and gene therapy clinical trials. It ensures compliance with FDA, EMA, CDSCO, WHO, and ICH GCP/GMP requirements, covering traceability, custody, product handling, and regulatory oversight.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}

Standard Operating Procedure for Chain of Identity & Chain of Custody (Cell/Gene)

Purpose

The purpose of this SOP is to define the processes required to maintain Chain of Identity (CoI) and Chain of Custody (CoC) for cell and gene therapy products used in clinical trials. These processes ensure traceability, product integrity, subject safety, and regulatory compliance from collection through administration and follow-up.

Scope

This SOP applies to sponsors, investigators, CROs, laboratories, GMP manufacturing facilities, couriers, and site staff involved in ATMP (Advanced Therapy Medicinal Product) clinical trials. It covers sample collection, labeling, custody transfers, product tracking, custody documentation, and archival of records.

Responsibilities

• Sponsor: Oversees CoI/CoC processes and ensures regulatory compliance.
• Investigator: Ensures subject-specific identity verification at site level.
• GMP Facility: Maintains manufacturing custody records and certificates of analysis.
• CRO: Monitors CoI/CoC compliance across sites and vendors.
• Courier: Maintains custody during product transportation.
• QA: Audits CoI/CoC logs for accuracy and completeness.

Accountability

The Sponsor’s ATMP Quality Lead is accountable for overall compliance with Chain of Identity and Chain of Custody procedures. The Investigator is accountable for subject-level verification prior to administration.

Procedure

1. Chain of Identity (CoI)
1.1 Assign unique subject-specific identifiers at time of collection.
1.2 Verify identifiers at each step: collection, processing, manufacturing, and administration.
1.3 Document in Chain of Identity Log (Annexure-1).

2. Chain of Custody (CoC)
2.1 Record all custody transfers from collection through manufacturing, shipment, storage, and administration.
2.2 Use controlled custody forms signed by transferring and receiving personnel.
2.3 Maintain records in Chain of Custody Log (Annexure-2).

3. Custody Transfer
3.1 At each transfer, verify subject identifier, product batch/lot number, and condition.
3.2 Document signatures, date, and time for both transferring and receiving parties.

4. Manufacturing and Quality Control
4.1 GMP facility verifies CoI before initiating processing.
4.2 Issue Certificate of Analysis linked to subject-specific identifiers.

5. Shipment and Storage
5.1 Use validated containers and cold-chain requirements.
5.2 Record shipment details in Custody Transfer Log (Annexure-3).

6. Administration at Site
6.1 Prior to administration, Investigator verifies subject identifier against CoI records.
6.2 Document in Site Administration Log (Annexure-4).

7. Archiving
7.1 Archive all CoI/CoC records in TMF and ISF.
7.2 Retain per global ATMP regulations (minimum 25 years in some regions).

Abbreviations

• SOP: Standard Operating Procedure
• CoI: Chain of Identity
• CoC: Chain of Custody
• ATMP: Advanced Therapy Medicinal Products
• QA: Quality Assurance
• CRO: Contract Research Organization
• GMP: Good Manufacturing Practice
• TMF: Trial Master File
• ISF: Investigator Site File
• FDA: Food and Drug Administration
• EMA: European Medicines Agency
• CDSCO: Central Drugs Standard Control Organization
• WHO: World Health Organization

Documents

1. Chain of Identity Log (Annexure-1)
2. Chain of Custody Log (Annexure-2)
3. Custody Transfer Log (Annexure-3)
4. Site Administration Log (Annexure-4)

References

• FDA – Cellular & Gene Therapy Oversight
• EMA – ATMP Guidelines
• CDSCO – Cell & Gene Therapy Regulations
• ICH GCP – ATMP Trials
• WHO – ATMP Chain of Custody Recommendations

Version: 1.0

Approval Section

Annexures

Annexure-1: Chain of Identity Log

Annexure-2: Chain of Custody Log

Annexure-3: Custody Transfer Log

Annexure-4: Site Administration Log

Revision History

For more SOPs visit: Pharma SOP

{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.clinicalstudies.in/sop-for-gmp-compliant-handling-of-gene-cell-products-at-sites”
},
“headline”: “SOP for GMP-Compliant Handling of Gene/Cell Products at Sites”,
“description”: “This SOP defines procedures for GMP-compliant handling of gene and cell therapy products at clinical sites, ensuring compliance with FDA, EMA, CDSCO, WHO, and ICH GCP/GMP requirements. It covers receipt, storage, preparation, administration, and documentation of ATMPs.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}

Standard Operating Procedure for GMP-Compliant Handling of Gene/Cell Products at Sites

Purpose

The purpose of this SOP is to establish GMP-compliant procedures for handling gene and cell therapy products at clinical trial sites. Proper handling ensures product quality, subject safety, data integrity, and compliance with global regulatory requirements.

Scope

This SOP applies to investigators, pharmacists, laboratory staff, nurses, CROs, and sponsors involved in the handling of Advanced Therapy Medicinal Products (ATMPs) at clinical trial sites. It covers receipt, storage, thawing, reconstitution, preparation, administration, environmental controls, and documentation.

Responsibilities

• Sponsor: Provides handling instructions and ensures training of site staff.
• Investigator: Ensures site-level compliance with GMP handling requirements.
• Pharmacist/Authorized Site Staff: Manage receipt, storage, preparation, and accountability of ATMPs.
• Nurses: Administer ATMPs as per protocol and handling instructions.
• QA: Audits compliance with GMP and GCP requirements.

Accountability

The Principal Investigator is accountable for site-level GMP-compliant handling of gene and cell therapy products. The Sponsor’s ATMP Quality Head is accountable for overall oversight and regulatory compliance.

Procedure

1. Product Receipt
1.1 Verify product identity, batch/lot number, and condition upon arrival.
1.2 Record details in ATMP Receipt Log (Annexure-1).
1.3 Report discrepancies or damages immediately to sponsor and QA.

2. Storage
2.1 Store ATMPs in secure, access-controlled, validated storage (cryogenic/freezer).
2.2 Maintain continuous temperature monitoring with alarms.
2.3 Document in ATMP Storage Log (Annexure-2).

3. Preparation
3.1 Prepare products in a GMP-compliant cleanroom or aseptic environment.
3.2 Follow manufacturer’s instructions for thawing, reconstitution, or dilution.
3.3 Record all steps in ATMP Preparation Log (Annexure-3).

4. Administration
4.1 Verify subject ID against chain of identity records.
4.2 Administer under medical supervision as per protocol.
4.3 Document in ATMP Administration Log (Annexure-4).

5. Accountability
5.1 Reconcile doses received, prepared, administered, returned, or destroyed.
5.2 Maintain ATMP Accountability Log (Annexure-5).

6. Environmental Monitoring
6.1 Monitor cleanroom conditions (temperature, humidity, particle counts).
6.2 Document in Environmental Monitoring Log (Annexure-6).

7. Deviations and CAPA
7.1 Record handling deviations in Deviation Log (Annexure-7).
7.2 Implement CAPA for deviations impacting quality or compliance.

8. Archiving
8.1 Archive all ATMP handling logs in TMF/ISF.
8.2 Retain per regulatory requirements (25 years for ATMPs in EU).

Abbreviations

• SOP: Standard Operating Procedure
• ATMP: Advanced Therapy Medicinal Products
• GMP: Good Manufacturing Practice
• GCP: Good Clinical Practice
• QA: Quality Assurance
• CRO: Contract Research Organization
• PI: Principal Investigator
• TMF: Trial Master File
• ISF: Investigator Site File

Documents

1. ATMP Receipt Log (Annexure-1)
2. ATMP Storage Log (Annexure-2)
3. ATMP Preparation Log (Annexure-3)
4. ATMP Administration Log (Annexure-4)
5. ATMP Accountability Log (Annexure-5)
6. Environmental Monitoring Log (Annexure-6)
7. Deviation Log (Annexure-7)

References

• FDA – GMP for Cellular & Gene Therapy Products
• EMA – ATMP GMP Guidelines
• CDSCO – ATMP Handling Rules
• ICH GCP – GMP Interface for ATMPs
• WHO – Advanced Therapies GMP Standards

Version: 1.0

Approval Section

Annexures

Annexure-1: ATMP Receipt Log

Annexure-2: ATMP Storage Log

Annexure-3: ATMP Preparation Log

Annexure-4: ATMP Administration Log

Annexure-5: ATMP Accountability Log

Annexure-6: Environmental Monitoring Log

Annexure-7: Deviation Log

Revision History

For more SOPs visit: Pharma SOP

{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.clinicalstudies.in/sop-for-long-term-follow-up-ltfu-of-atmp-subjects”
},
“headline”: “SOP for Long-Term Follow-Up (LTFU) of ATMP Subjects”,
“description”: “This SOP outlines the standardized procedures for long-term follow-up (LTFU) of subjects in Advanced Therapy Medicinal Product (ATMP) trials, ensuring compliance with FDA, EMA, CDSCO, WHO, and ICH GCP requirements. It includes subject re-consent, monitoring, safety reporting, and data retention strategies.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}

Standard Operating Procedure for Long-Term Follow-Up (LTFU) of ATMP Subjects

Purpose

The purpose of this SOP is to define standardized procedures for the long-term follow-up (LTFU) of subjects enrolled in Advanced Therapy Medicinal Product (ATMP) clinical trials. Due to the potential for delayed adverse events, gene integration risks, and long-term immunogenicity, subjects must be followed beyond the trial’s active treatment phase to ensure safety and regulatory compliance.

Scope

This SOP applies to sponsors, investigators, CROs, site staff, and regulatory affairs involved in ATMP trials. It covers subject re-consent, follow-up visits, safety reporting, data collection, data privacy, retention, regulatory submissions, and communication with subjects during extended follow-up.

Responsibilities

• Sponsor: Designs and funds LTFU programs, ensuring compliance with regional and international regulations.
• Investigator: Manages LTFU at site level, ensuring subject safety and documentation.
• CRO: Oversees monitoring and ensures adherence to LTFU requirements.
• Regulatory Affairs: Submits updates to authorities and ethics committees.
• QA: Audits LTFU records and ensures data integrity.

Accountability

The Sponsor’s Medical Director is accountable for overall LTFU compliance. The Principal Investigator is accountable for subject-level follow-up and re-consent.

Procedure

1. LTFU Planning
1.1 Develop an LTFU plan as part of the trial protocol.
1.2 Define follow-up duration (e.g., 5–25 years depending on ATMP type).
1.3 Record in LTFU Planning Log (Annexure-1).

2. Subject Re-Consent
2.1 Obtain re-consent if required by protocol or local regulations.
2.2 Document in Re-Consent Log (Annexure-2).

3. Follow-Up Visits
3.1 Schedule annual or protocol-defined follow-up visits.
3.2 Collect clinical, laboratory, and imaging data.
3.3 Document visits in Follow-Up Visit Log (Annexure-3).

4. Safety Reporting
4.1 Monitor delayed adverse events, malignancies, or gene integration effects.
4.2 Report per regulatory timelines to sponsor, EC/IRB, and regulators.
4.3 Document in LTFU Safety Log (Annexure-4).

5. Data Privacy and Retention
5.1 Ensure compliance with GDPR, HIPAA, and local privacy laws.
5.2 Retain records for minimum of 25 years for ATMPs in EU.
5.3 Record retention activities in Data Retention Log (Annexure-5).

6. Subject Communication
6.1 Provide regular updates and educational material to subjects.
6.2 Document communication in Subject Communication Log (Annexure-6).

7. Archiving
7.1 Archive all LTFU records in TMF and ISF.
7.2 Ensure accessibility for inspections and audits.

Abbreviations

• SOP: Standard Operating Procedure
• LTFU: Long-Term Follow-Up
• ATMP: Advanced Therapy Medicinal Products
• CRO: Contract Research Organization
• QA: Quality Assurance
• IRB/EC: Institutional Review Board/Ethics Committee
• GCP: Good Clinical Practice
• TMF: Trial Master File
• ISF: Investigator Site File
• GDPR: General Data Protection Regulation
• HIPAA: Health Insurance Portability and Accountability Act

Documents

1. LTFU Planning Log (Annexure-1)
2. Re-Consent Log (Annexure-2)
3. Follow-Up Visit Log (Annexure-3)
4. LTFU Safety Log (Annexure-4)
5. Data Retention Log (Annexure-5)
6. Subject Communication Log (Annexure-6)

References

• FDA – Long-Term Follow-Up for Cellular & Gene Therapy
• EMA – ATMP LTFU Guidelines
• CDSCO – ATMP Long-Term Monitoring
• ICH GCP – Follow-Up in ATMP Trials
• WHO – ATMP Long-Term Follow-Up Recommendations

Version: 1.0

Approval Section

Annexures

Annexure-1: LTFU Planning Log

Annexure-2: Re-Consent Log

Annexure-3: Follow-Up Visit Log

Annexure-4: LTFU Safety Log

Annexure-5: Data Retention Log

Annexure-6: Subject Communication Log

Revision History

For more SOPs visit: Pharma SOP

{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.clinicalstudies.in/sop-for-traceability-of-cell-tissue-based-products”
},
“headline”: “SOP for Traceability of Cell/Tissue-Based Products”,
“description”: “This SOP establishes standardized procedures for traceability of cell and tissue-based products in ATMP clinical trials. It ensures compliance with FDA, EMA, CDSCO, WHO, and ICH GCP/GMP requirements, covering donor-to-recipient linkage, custody, product labeling, and record retention.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}

Standard Operating Procedure for Traceability of Cell/Tissue-Based Products

Purpose

The purpose of this SOP is to define standardized procedures for traceability of cell and tissue-based products used in clinical trials of Advanced Therapy Medicinal Products (ATMPs). Traceability ensures donor-to-patient linkage, product integrity, subject safety, and regulatory compliance throughout collection, processing, distribution, administration, and long-term follow-up.

Scope

This SOP applies to sponsors, investigators, CROs, GMP facilities, laboratories, couriers, and site staff engaged in cell and tissue-based ATMP clinical trials. It covers subject-product linkage, chain of identity, chain of custody, labeling, lot-to-subject mapping, and archival of traceability records.

Responsibilities

• Sponsor: Ensures global traceability oversight and regulatory compliance.
• Investigator: Maintains subject-level traceability records and ensures verification before administration.
• GMP Facility: Maintains donor-to-product and product-to-recipient traceability logs.
• CRO: Verifies compliance with traceability SOPs across sites and vendors.
• Courier: Maintains custody logs for transported products.
• QA: Reviews traceability records and ensures inspection readiness.

Accountability

The Sponsor’s ATMP Traceability Lead is accountable for ensuring complete traceability records across the supply and clinical chain. Investigators are accountable for verification prior to administration.

Procedure

1. Donor/Subject Identification
1.1 Assign unique donor identifiers at collection.
1.2 Assign recipient/subject identifiers and link them to donor IDs where applicable.
1.3 Document in Donor-Recipient Linkage Log (Annexure-1).

2. Chain of Identity (CoI)
2.1 Verify donor and recipient identifiers at all steps.
2.2 Maintain subject-product linkage documentation.
2.3 Record in Chain of Identity Log (Annexure-2).

3. Chain of Custody (CoC)
3.1 Document custody transfers from collection to administration.
3.2 Require signatures from transferring and receiving parties.
3.3 Record in Chain of Custody Log (Annexure-3).

4. Product Labeling
4.1 Labels must contain donor ID, recipient ID, batch/lot number, storage conditions, and cautionary statements.
4.2 Verify label legibility and accuracy before use.
4.3 Record in Label Verification Log (Annexure-4).

5. Lot-to-Subject Mapping
5.1 Map each product batch or lot to corresponding subject IDs.
5.2 Record in Lot-to-Subject Mapping Log (Annexure-5).

6. Traceability During Follow-Up
6.1 Track product-related adverse events, defects, or recalls.
6.2 Document in Follow-Up Traceability Log (Annexure-6).

7. Archiving
7.1 Archive all traceability records in TMF and ISF.
7.2 Retain for minimum of 25 years or as required by regional laws.

Abbreviations

• SOP: Standard Operating Procedure
• ATMP: Advanced Therapy Medicinal Products
• CoI: Chain of Identity
• CoC: Chain of Custody
• QA: Quality Assurance
• CRO: Contract Research Organization
• GMP: Good Manufacturing Practice
• TMF: Trial Master File
• ISF: Investigator Site File
• FDA: Food and Drug Administration
• EMA: European Medicines Agency
• CDSCO: Central Drugs Standard Control Organization
• WHO: World Health Organization

Documents

1. Donor-Recipient Linkage Log (Annexure-1)
2. Chain of Identity Log (Annexure-2)
3. Chain of Custody Log (Annexure-3)
4. Label Verification Log (Annexure-4)
5. Lot-to-Subject Mapping Log (Annexure-5)
6. Follow-Up Traceability Log (Annexure-6)

References

• FDA – Cell and Gene Therapy Traceability
• EMA – ATMP Traceability Guidance
• CDSCO – Traceability of Tissue and Cell-Based Products
• ICH GCP – Traceability and Record Keeping
• WHO – Traceability of Biological Products

Version: 1.0

Approval Section

Annexures

Annexure-1: Donor-Recipient Linkage Log

Annexure-2: Chain of Identity Log

Annexure-3: Chain of Custody Log

Annexure-4: Label Verification Log

Annexure-5: Lot-to-Subject Mapping Log

Annexure-6: Follow-Up Traceability Log

Revision History

For more SOPs visit: Pharma SOP

{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.clinicalstudies.in/sop-for-vaccine-trial-cold-chain-management-mass-trials”
},
“headline”: “SOP for Vaccine Trial Cold-Chain Management (Mass Trials)”,
“description”: “This SOP defines standardized procedures for cold-chain management in vaccine clinical trials, particularly mass vaccination trials. It ensures compliance with FDA, EMA, CDSCO, WHO, and ICH GCP requirements, covering receipt, storage, transport, monitoring, accountability, and deviation handling of vaccines.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}

Standard Operating Procedure for Vaccine Trial Cold-Chain Management (Mass Trials)

Purpose

The purpose of this SOP is to establish standardized procedures for cold-chain management of vaccines in clinical trials, with a focus on large-scale and mass vaccination trials. Proper cold-chain practices ensure product stability, subject safety, and compliance with international regulatory requirements.

Scope

This SOP applies to sponsors, CROs, investigators, site pharmacists, couriers, and laboratory staff involved in the receipt, storage, transport, and distribution of vaccines used in clinical trials. It covers cold-chain monitoring, accountability, excursion management, multi-site logistics, and regulatory compliance.

Responsibilities

• Sponsor: Ensures validated cold-chain systems are in place and audits compliance.
• Investigator: Oversees vaccine receipt, storage, and distribution at site level.
• Pharmacist/Site Staff: Responsible for storage, monitoring, accountability, and reporting deviations.
• CRO: Monitors adherence to cold-chain requirements across sites.
• Courier: Maintains validated shipping conditions during transport.
• QA: Audits cold-chain management and reviews deviation reports.

Accountability

The Sponsor’s Vaccine Supply Chain Lead is accountable for cold-chain compliance. The Investigator is accountable for site-level cold-chain management.

Procedure

1. Vaccine Receipt
1.1 Verify shipment condition, temperature monitors, and integrity upon arrival.
1.2 Document details in Vaccine Receipt Log (Annexure-1).
1.3 Report discrepancies immediately to sponsor and QA.

2. Storage
2.1 Store vaccines in validated refrigerators/freezers with continuous monitoring.
2.2 Maintain temperature ranges (e.g., +2°C to +8°C or per product label).
2.3 Document in Vaccine Storage Log (Annexure-2).

3. Distribution and Transport
3.1 Use validated shippers and cold-chain packaging.
3.2 Document distribution in Vaccine Distribution Log (Annexure-3).

4. Temperature Monitoring
4.1 Use calibrated data loggers with alarms.
4.2 Review temperature records daily.
4.3 Record in Temperature Monitoring Log (Annexure-4).

5. Excursion Management
5.1 Document all excursions in Excursion Log (Annexure-5).
5.2 Notify sponsor QA and regulatory authorities if excursions exceed thresholds.

6. Accountability
6.1 Reconcile doses received, used, destroyed, or returned.
6.2 Record in Vaccine Accountability Log (Annexure-6).

7. Multi-Site Logistics
7.1 Coordinate shipments across sites with validated logistics partners.
7.2 Document in Multi-Site Logistics Log (Annexure-7).

8. Archiving
8.1 Archive all cold-chain records in TMF and ISF.
8.2 Retain records per regulatory requirements.

Abbreviations

• SOP: Standard Operating Procedure
• QA: Quality Assurance
• CRO: Contract Research Organization
• TMF: Trial Master File
• ISF: Investigator Site File
• GCP: Good Clinical Practice
• FDA: Food and Drug Administration
• EMA: European Medicines Agency
• CDSCO: Central Drugs Standard Control Organization
• WHO: World Health Organization

Documents

1. Vaccine Receipt Log (Annexure-1)
2. Vaccine Storage Log (Annexure-2)
3. Vaccine Distribution Log (Annexure-3)
4. Temperature Monitoring Log (Annexure-4)
5. Excursion Log (Annexure-5)
6. Vaccine Accountability Log (Annexure-6)
7. Multi-Site Logistics Log (Annexure-7)

References

• FDA – Vaccine Trial Guidelines
• EMA – Vaccine Storage & Transport Guidance
• CDSCO – Vaccine Cold-Chain Rules
• ICH GCP – Cold Chain and Vaccine Trials
• WHO – Cold Chain and Immunization Guidelines

Version: 1.0

Approval Section

Annexures

Annexure-1: Vaccine Receipt Log

Annexure-2: Vaccine Storage Log

Annexure-3: Vaccine Distribution Log

Annexure-4: Temperature Monitoring Log

Annexure-5: Excursion Log

Annexure-6: Vaccine Accountability Log

Annexure-7: Multi-Site Logistics Log

Revision History

For more SOPs visit: Pharma SOP